About
Dr. Kan Chen is a Partner at Qiming Venture Partners and co-leads the firm's healthcare investing. Before joining Qiming in 2016, he worked at Harvard Medical School, the Cleveland Clinic, Johnson & Johnson, and Hengrui Pharma, building a background in immunology, oncology, and drug discovery. He has served on numerous biotech boards, including Connect Biopharma and TandemAI-related portfolio roles, and is a cross-border healthcare investor active between China and the U.S.
Areas of interest
biotechdrug discoveryimmunologyoncologyautoimmune diseasecardiovascular diseaseAI drug discoveryepigenetic medicineRNA therapeuticsproteomicsdiagnosticsdigital health